NCT07472946

Brief Summary

This study is a prospective, single-blind, randomized controlled trial designed to investigate the effects of whole-body vibration (WBV) exercise on balance, mobility, fall risk, and proprioception in patients with Parkinson's disease. A total of 68 patients diagnosed with Parkinson's disease, aged between 50 and 75 years, will be recruited from the outpatient clinic of the Department of Physical Medicine and Rehabilitation at Istanbul University, Istanbul Faculty of Medicine. Eligible participants will be clinically stable (no medication changes within the last 3 months), classified as Hoehn and Yahr stage 1-3, and MDS-UPDRS stage 2-3. Written informed consent will be obtained from all participants before enrollment. Participants will be randomly assigned in a 1:1 ratio to either the intervention group (n=34) or the control group (n=34). Randomization will be performed using a computer-generated random allocation sequence. Outcome assessments will be conducted by a blinded assessor. The intervention group will receive whole-body vibration (WBV) training in addition to a standardized home exercise program. WBV sessions will be performed using the Power Plate pro5 vibration platform (Performance Health Systems, LLC, Northbrook, IL, USA). Training will be conducted three times per week for 8 weeks (24 sessions total). Each session will include 5 sets of vibration exposure, consisting of 1 minute of vibration followed by 1 minute of rest. Exercises will be performed in semi-squat and lunge positions. Vibration parameters will be set at 6 Hz frequency with 2-4 mm amplitude. Sessions will be scheduled during the "on" phase of dopaminergic medication. Each session will include a 10-minute warm-up and a 5-minute cool-down period. The control group will perform only the standardized home exercise program. Both groups will receive initial in-clinic instruction for the home exercise program, which includes posture exercises, breathing and relaxation exercises, lower extremity active range-of-motion exercises, stretching, quadriceps strengthening, terminal knee extension exercises, rhythmic gait training, and balance/coordination/proprioceptive exercises. Home exercises will be performed three times per week for 8 weeks, lasting 30-45 minutes per session. Participants will be contacted weekly to monitor adherence. Outcome assessments will be conducted at baseline, at 8 weeks (post-intervention), and at 16 weeks (follow-up). The primary outcome measure is the Berg Balance Scale (BBS). Secondary outcome measures include:

  • Timed Up and Go (TUG) test
  • Six-Minute Walk Test (6MWT)
  • Fall Risk Index measured by computerized static posturography (TETRAX®)
  • Knee joint position sense measured using an isokinetic dynamometer (Biodex System 3 Pro), calculated as absolute angular error The primary analysis will evaluate changes in BBS scores between groups across time points using repeated measures analysis of variance. Secondary outcomes will be analyzed using similar statistical methods. Statistical significance will be set at p \< 0.05. The study aims to determine whether WBV combined with a home exercise program provides superior improvements in balance, mobility, fall risk, and proprioception compared with a home exercise program alone in individuals with Parkinson's disease.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
68

participants targeted

Target at P50-P75 for not_applicable

Timeline
2mo left

Started Apr 2026

Shorter than P25 for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress43%
Apr 2026Jul 2026

First Submitted

Initial submission to the registry

February 22, 2026

Completed
22 days until next milestone

First Posted

Study publicly available on registry

March 16, 2026

Completed
16 days until next milestone

Study Start

First participant enrolled

April 1, 2026

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2026

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 30, 2026

Last Updated

March 16, 2026

Status Verified

March 1, 2026

Enrollment Period

3 months

First QC Date

February 22, 2026

Last Update Submit

March 13, 2026

Conditions

Keywords

parkinson's diseasewhole body vibration exercisebalancemobilitygaitproprioception

Outcome Measures

Primary Outcomes (1)

  • Balance assessed by Berg Balance Scale (BBS)

    Balance will be assessed using the Berg Balance Scale (BBS), a 14-item clinical scale that evaluates static and dynamic balance abilities. Each item is scored from 0 to 4, yielding a total score ranging from 0 to 56. Higher scores indicate better balance performance.

    From baseline to 8 weeks (end of intervention)

Study Arms (2)

Whole-Body Vibration Plus Home Exercise

EXPERIMENTAL
Device: Whole-Body Vibration Plus Home Exercise

Home Exercise Program Only

ACTIVE COMPARATOR
Other: Home Exercise Only

Interventions

Participants in this arm will receive whole-body vibration (WBV) training in addition to a standardized home exercise program. WBV will be performed using the Power Plate pro5 platform, three times per week for 8 weeks (24 sessions). Each session will include 5 sets of 1-minute vibration with 1-minute rest intervals in semi-squat and lunge positions (6 Hz, 2-4 mm amplitude). Sessions will include a short warm-up and cool-down period. The home exercise program will consist of posture, breathing, stretching, strengthening, gait training, and balance/proprioceptive exercises, performed three times weekly for 8 weeks (30-45 minutes per session).

Whole-Body Vibration Plus Home Exercise

Participants in this arm will receive a standardized home exercise program only. The program will include posture training, breathing and relaxation exercises, lower extremity active range-of-motion and stretching exercises, quadriceps strengthening, terminal knee extension exercises, rhythmic gait training, and balance/coordination/proprioceptive exercises. Participants will receive initial in-clinic instruction and written guidance. Exercises will be performed three times per week for 8 weeks, with each session lasting approximately 30-45 minutes. Participants will be contacted weekly to monitor adherence.

Home Exercise Program Only

Eligibility Criteria

Age50 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age between 50 and 75 years
  • Clinical diagnosis of Parkinson's disease
  • Hoehn and Yahr stage 1-3
  • MDS-UPDRS stage 2-3
  • Clinically stable (no change in antiparkinsonian medication or treatment plan within the last 3 months)
  • Ability to stand independently and participate in exercise sessions
  • Provided written informed consent

You may not qualify if:

  • Participation in an inpatient or outpatient rehabilitation program within the last 3 months
  • Diagnosis of dementia or significant cognitive/communication impairment
  • Contraindications to whole-body vibration (e.g., severe peripheral neuropathy affecting vibration perception, epilepsy, pregnancy, metal implants or joint prostheses in the lower extremities, cardiac or brain pacemaker, uncontrolled hypertension, history of acute thrombosis)
  • Presence of additional neurological disorders affecting balance or neuromuscular performance
  • Functional Ambulation Classification (FAC) level 0-2
  • Musculoskeletal conditions preventing safe standing on the vibration platform (e.g., fracture, ulcer, acute injury)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Research Assistant

Study Record Dates

First Submitted

February 22, 2026

First Posted

March 16, 2026

Study Start

April 1, 2026

Primary Completion (Estimated)

June 30, 2026

Study Completion (Estimated)

July 30, 2026

Last Updated

March 16, 2026

Record last verified: 2026-03